Findings

What do systematic reviews say?

5 questions · 5 findings · 1 reviews · Heart

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 20%Moderate 3 · 60%High 1 · 20%

Mineralocorticoid receptor antagonists (MRAs) vs placebo or no treatment

Quality of life (MLHFQ): from 0 to 105 · patients with chronic heart failure with preserved ejection fraction

1 finding from 1 review

Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 511 participants
Low

Mineralocorticoid receptor antagonists (MRAs) vs placebo or no treatment

Cardiovascular mortality · patients with chronic heart failure with preserved ejection fraction

Mineralocorticoid receptor antagonists (MRAs) showed no clear difference in cardiovascular mortality (RR) compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
RR 0.9 [0.74, 1.11]
3 studies · 4070 participants
Moderate

Mineralocorticoid receptor antagonists (MRAs) vs placebo or no treatment

Heart failure hospitalisation (RR) · patients with chronic heart failure with preserved ejection fraction

Mineralocorticoid receptor antagonists (MRAs) probably leads to lower heart failure hospitalisation (RR) compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
RR 0.82 [0.69, 0.98]
3 studies · 3714 participants
Moderate

Mineralocorticoid receptor antagonists (MRAs) vs placebo or no treatment

Hyperkalaemia · patients with chronic heart failure with preserved ejection fraction

Mineralocorticoid receptor antagonists (MRAs) leads to higher hyperkalaemia compared with placebo or no treatment (high certainty).

1 finding from 1 review

Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
RR 2.11 [1.77, 2.52]
6 studies · 4291 participants
High

Mineralocorticoid receptor antagonists (MRAs) vs placebo or no treatment

All‐cause mortality · patients with chronic heart failure with preserved ejection fraction

Mineralocorticoid receptor antagonists (MRAs) showed no clear difference in all‐cause mortality compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved… 2021 · Cochrane Headline outcomes only
RR 0.91 [0.78, 1.06]
5 studies · 4207 participants
Moderate